Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23065111 | 0.88 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL23065093 | 0.87 | TP53 (0.50) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL24089980 | 0.87 | ALDH1A1 (0.51) | KMT2APDE4BPDE7A | |
| SCHEMBL23064692 | 0.81 | TP53 (0.47) | — | |
| SCHEMBL24089999 | 0.80 | MAPT (0.50) | KMT2APDE4BPDE7A | |
| SCHEMBL23065144 | 0.80 | PDE7A (0.52) | PIK3CDPIK3CGPDE4BPDE7A | |
| SCHEMBL24090125 | 0.79 | PIK3CD (0.50) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL23065090 | 0.78 | C1R (0.48) | PDE4BPDE7A | |
| SCHEMBL18923546 | 0.77 | HRH3 (0.57) | PIK3CDPIK3R1 | |
| SCHEMBL23065109 | 0.76 | SMN1; SMN2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
| WO-2021039968-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | PIK3CD 4554/4885PIK3R1 3904/4885PIK3CA 4389/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | PIK3CD 4497/4885PIK3R1 4054/4885PIK3CA 4289/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | PIK3CD 4497/4885PIK3R1 4054/4885PIK3CA 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.